PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New clinical study to advance development of treatments for liver cirrhosis

The £30m ADVANCE study is the most extensive study into liver disease worldwide.

A new study involving Boehringer Ingelheim, Newcastle University and the University of Edinburgh has been announced to advance the development of new treatments for liver cirrhosis.

The Accelerating Discovery: Actionable NASH Cirrhosis Endpoints (ADVANCE) study is the most extensive study into liver cirrhosis ever conducted worldwide.

Estimated to affect 444 million people globally, non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH) is an inflammatory liver disease caused by a build-up of fat in the liver.

Over time, NASH can cause the formation of scar tissue, which can lead to liver cirrhosis – scarring of the liver that prevents the liver from working properly.

Funded by Boehringer Ingelheim, the £30m ADVANCE study will advance understandings of the condition and help identify translational biomarkers to accelerate the development of future therapies.

Recruited from specialist liver clinics at hospitals across the UK and Europe, through referral by their treating physician, the study will involve 200 patients who have been diagnosed with or are at risk of advanced fibrosis or cirrhosis due to metabolic dysfunction-associated steatotic liver disease.

Harnessing Edinburgh University’s single cell RNA sequencing technology, small samples of liver tissue will be collected using biopsies to assess detailed changes in gene expression in the liver and patients will receive blood tests and MRI scans across the next two years.

Led by doctors at Newcastle University and Edinburgh University and scientists at Boehringer Ingelheim, all the data generated will be combined for researchers to see how disease-related changes occur and evolve in the body as cirrhosis progresses.

In addition, specialist doctors and researchers from universities and hospitals across Europe, including Belgium, France, the UK, Spain and Italy will be involved in the international consortium.

The pharmaceutical company looks forward to “better [understanding] the underlying disease processes and [bringing] much-needed new treatments to patients with liver cirrhosis” through the ADVANCE study, said Lykke Hinsch Gylvin, chief medical officer, Boehringer Ingelheim.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026